Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00036062 · ClinicalTrials.gov registry record · Phase 1

A Phase II Study to Determine the Efficacy and Safety of Sivelestat in Subjects With Acute Lung Injury

A Phase 1 study of Acute Lung Injury and Respiratory Distress Syndrome, Adult, sponsored by Eli Lilly and Company.

Completed
Registry status
Phase 1
Development phase
600
Enrollment target
20
Study locations

NCT00036062: Completed Phase 1 study of Acute Lung Injury and Respiratory Distress Syndrome, Adult, sponsored by Eli Lilly and Company.

NCT00036062 is a Phase 1 study of Acute Lung Injury and Respiratory Distress Syndrome, Adult that has completed, run by Eli Lilly and Company. The registered enrollment target is 600 participants, above the 66-participant average among 10 other Acute Lung Injury trials with a reported enrollment target (809% higher). The trial reports 20 study locations across 10 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00036062, a Phase 1 study of Acute Lung Injury and Respiratory Distress Syndrome, Adult, has completed, sponsored by Eli Lilly and Company.

COMPLETED
Registry status
Phase 1
Development phase
600 participants
Enrollment target
20
Study locations

Study Summary

The purpose of this study is to determine whether sivelestat will reduce the amount of time a patient must spend on a ventilator and/or increase the chance of survival of patients with acute lung injury.

Conditions Studied

Acute Lung Injury Respiratory Distress Syndrome, Adult

Interventions

  • DRUG Sivelestat

Study Locations (20)

Illinois

  • - Chicago
  • - Elk Grove Village
  • - Maywood
  • - North Chicago

California

  • - Orange
  • - Sacramento
  • - San Diego

Florida

  • - Bay Pines
  • - Clearwater
  • - Fort Lauderdale

Arizona

  • - Phoenix
  • - Tucson

Colorado

  • - Denver
  • - Englewood

Georgia

  • - Augusta
  • - Austell

Alabama

  • - Birmingham

Connecticut

  • - New Haven

Trial Details

FieldValue
Enrollment Target 600 participants
Start Date 2001-08
Est. Completion 2002-12
Phase Phase 1
Eli Lilly and Company

1,341 total trials

What the finished NCT00036062 record still lists

NCT00036062 is an interventional study that assigns participants to a tested intervention. The registered 600 participants enrollment target is mid-sized for trials with a published cap, above the 66-participant average among 10 other Acute Lung Injury trials with a reported enrollment target (809% higher).

The record links to 2 conditions, with Acute Lung Injury appearing as the primary indexed condition, and to 1 intervention - of which Sivelestat is the first listed.

NCT00036062 names 20 study sites across 10 states, led by Illinois, California, Florida.

Frequently Asked Questions

What is clinical trial NCT00036062 about?

NCT00036062 is a clinical study titled "A Phase II Study to Determine the Efficacy and Safety of Sivelestat in Subjects With Acute Lung Injury". The purpose of this study is to determine whether sivelestat will reduce the amount of time a patient must spend on a ventilator and/or increase the chance of survival of patients with acute lung injury.

What is the current status of trial NCT00036062?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 600 participants. The study started on 2001-08. Estimated completion is 2002-12.

What conditions does trial NCT00036062 study?

This clinical trial studies the following conditions: Acute Lung Injury, Respiratory Distress Syndrome, Adult.

What interventions are being tested in trial NCT00036062?

The interventions under investigation include: Sivelestat (DRUG).

Who is sponsoring clinical trial NCT00036062?

This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00036062 being conducted?

This trial has 20 study locations across Alabama, Arizona, California, Colorado, Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Acute Lung Injury

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT00036062's enrollment target sits among peer trials

600 1st of 10 higher than 10 of 10 other Acute Lung Injury trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Acute Lung Injury trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00004317 · 600 participants · Phase 4

    Pyrimethamine, Sulfadiazine, and Leucovorin in Treating Patients With Congenital Toxoplasmosis

  • NCT00209235 · 600 participants · NA

    Albright Hereditary Osteodystrophy: Natural History, Growth, and Cognitive/Behavioral Assessments

  • NCT01473784 · 600 participants · NA

    Transoral Robotic Surgery in Treating Patients With Benign or Malignant Tumors of the Head and Neck

  • NCT01866371 · 600 participants

    High Resolution Retinal Imaging

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Related registry views

Source: ClinicalTrials.gov NCT00036062, the US trial registry maintained by the National Library of Medicine. NCT00036062 (mid enrollment · wide site footprint · completed) retrieved and formatted by PlainTrial, see methodology.